News

Eli Lilly and Company: FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease
The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of the treatment INDIANAPOLIS, ...
The Malaysian Reserve10h
FDA approves updated label for Lilly’s Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer’s disease
The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to ...
MedPage Today15h
Well-Being Declines Before Mild Cognitive Impairment
Source Reference: Guo J, et al "Psychological well-being trajectories preceding incident mild cognitive impairment and dementia" J Neurol Neurosurg Psychiatry 2024; DOI: 10.1136/jnnp-2024-333837.